Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2019/07/020407
CTRI/2019/07/020407
Not yet recruiting
未知

STOP IMATINIB MESYLATE IN PATIENTS OF CHRONIC MYELOID LEUKEMIA- CHRONIC PHASE(CML-CP)- A PILOT STUDY. - ISTIM

DR BRA IRCH AIIMS0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
DR BRA IRCH AIIMS
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
DR BRA IRCH AIIMS

Eligibility Criteria

Inclusion Criteria

  • •a). Age \>\= 18 years
  • •b). CML\-CP on imatinib mesylate
  • •c). Optimal response to imatinib
  • •d). Minimum duration of imatinib mesylate treatment of 3 years
  • •e) At least complete molecular remission MR4
  • •f). Deep molecular remission duration should be at least one year
  • •g) Baseline data and documentation of treatment should be available for outside treated patients

Exclusion Criteria

  • •a) Patients who had CML\-accelerated phase/ blast crisis at diagnosis
  • •b) High Sokal score
  • •c). Not willing for the study
  • •d) Pregnancy
  • •e) Female patient not willing to use contraception
  • •f) Patients not willing for regular follow up

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Imatinib discontinuation for Chronic Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.
JPRN-UMIN000012472Epidemiological and Clinical Research Information Network (ECRIN)100
Completed
Phase 2
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group studyChronic Myeloid Leukemia Chronic phase
JPRN-UMIN000011971Japan Adult Leukemia Study Group62
Recruiting
Not Applicable
Stop imatinib or dasatinib study in CP-CML patients mainitaining complete molecular response for two yearschronic phase chronic myeloid leukemia
JPRN-UMIN000007944Tokyo Women's Medical University40
Completed
Phase 2
Dasatinib discontinuation for Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission.chronic myeloid leukemia
JPRN-UMIN000005130Epidemiological and Clinical Research Information Network (ECRIN)50
Active, not recruiting
Phase 1
Arrest Imatinib or Dasatinib in CML patients with Deep Molecular ResponsesChronic phase CML patients with BCR-ABL/ABLIS transcript levels below MR3 (<0.1%) and aboveMR4.5 (>0.0032%) at the time of accrual.MedDRA version: 20.0Level: LLTClassification code 10009015Term: Chronic myeloid leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Immune System Diseases [C20]
EUCTR2014-001603-42-ITAIL CATANIA ASSOCIAZIONE ITALIANA CONTRO LEUCEMIE-LINFOMI E MIELOMA ONLUS222